Antigen is Required for the Activation of Effector Activities, Whereas Interleukin 2 Is Required for the Maintenance of Memory in Ovalbumin-specific, CD8+ Cytotoxic T Lymphocytes
Overview
General Medicine
Affiliations
The mechanisms that maintain memory in T cells are not completely understood. We have investigated the role of antigen and interleukin (IL)-2 in the growth and maintenance of CD8+ T cells using a cytolytic T cell line specific for ovalbumin (OVA)257-264 presented by H-2Kb. This line does not secrete IL-4 or IL-2; hence, stimulation with the OVA-transfected EL4 line (E.G7-OVA) does not induce proliferation without addition of exogenous growth factors. Furthermore, this line can be maintained continuously by weekly addition of irradiated, splenic filler cells and IL-2, with or without E.G7-OVA. Although IL-2 induced proliferation of these cytotoxic T lymphocytes (CTLs), production of interferon gamma and tumor necrosis factor alpha required stimulation of the CTL with E. G7-OVA. The kinetics of lymphokine secretion after stimulation by E. G7-OVA were the same whether the CTL had been maintained with or without antigen (Ag). In addition, both CTL lines killed E.G7-OVA target cells within 4 h. Thus, the effector functions of these CTLs were rapidly induced by T cell receptor (TCR) occupancy. CTLs cultured with or without Ag also served as memory T cells when parked for 100 d in unirradiated, syngeneic recipients without OVA. In the absence of OVA, the precursor frequency was identical in spleens of normal and beta2-microglobulin knockout recipients, but significantly less in IL-2 knockout mice. The decline of memory in the absence of IL-2 supports data from other investigators, suggesting that cell cycling is important to the maintenance of CD8+ T cell memory. These data also suggest that stimulation of OVA-specific CTLs by lymphokines seems to be more important to maintaining memory than stimulation of TCRs by cross-reactive peptides complexed to class I molecules.
Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy.
Morante V, Borghi M, Farina I, Michelini Z, Grasso F, Gallinaro A Viruses. 2021; 13(2).
PMID: 33672349 PMC: 7927015. DOI: 10.3390/v13020355.
Kim K, Kim H, Kim B, Kwon Y, Kim H, Kim Y Stem Cell Res Ther. 2018; 9(1):208.
PMID: 30092847 PMC: 6085688. DOI: 10.1186/s13287-018-0948-4.
Wagner Jr D Front Endocrinol (Lausanne). 2017; 8:208.
PMID: 28878738 PMC: 5572340. DOI: 10.3389/fendo.2017.00208.
Raiden S, Sananez I, Remes-Lenicov F, Pandolfi J, Romero C, De Lillo L J Infect Dis. 2017; 215(7):1049-1058.
PMID: 28199704 PMC: 5853597. DOI: 10.1093/infdis/jix070.
Early Subretinal Allograft Rejection Is Characterized by Innate Immune Activity.
Kennelly K, Holmes T, Wallace D, OFarrelly C, Keegan D Cell Transplant. 2017; 26(6):983-1000.
PMID: 28105976 PMC: 5657747. DOI: 10.3727/096368917X694697.